effect of semaglutide on chronic kidney disease Long-term outcomes in obesity and cardiovascular in the SELECT trial flow trial semaglutide kidney outcomes
Description
about 14% with semaglutide over 72 weeks
Although the first GLP-1s were approved for weight loss in 2014, usage surged in 2021
Fox Foundation to present an overview on the current clinical trials landscape for Parkinsons
It is a medically backed treatment designed to help you lose weight safely and sustainably under the care of a board-certified specialist
The STEP-HFpEF trial was designed to evaluate the effects of treatment on symptoms and physical limitations, exercise function and inflammation, along with body weight, and was, therefore, not powered to assess clinical endpoints such as HF hospitalizations
